BOOSTRIX - Medsafe Home Page

1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.

  Information, Boostrix

ADVANTAN Presentation Uses - Medsafe

ADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.

  Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate

LOXALATE 1. Product Name - Medsafe Home Page

Page 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.

  Risks, Combination

DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …

New Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …

  Sheet, Data, Data sheet, Clexane

SEPTANEST Articaine hydrochloride 4% with …

SEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.

  Articaine

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a

  Cymevene

Edition Draft - Medsafe

Part 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for

  Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice

Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …

New Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …

  Product, Name, Sheet, Data, Data sheet 1 product name

NEW ZEALAND DATA SHEET MESTINON® - Medsafe

NEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to

  Myasthenia, Gravis, Myasthenia gravis, Mestinon

DATA SHEET PREDNISONE - Medsafe

• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since

  Myasthenia, Gravis, Myasthenia gravis, Prednisone

AUSTRALIAN PRODUCT INFORMATION PANADOL …

5 4.9 OVERDOSE Poisons Information Centre If an overdose is taken or suspected, contact the Poisons Information Centre immediately for advice (131 126), or the patient should go to the nearest hospital straight away.

  Overdose, Panadol

REPORT OF TRANSFUSION ADVERSE REACTION …

REPORT OF TRANSFUSION ADVERSE REACTION TO BLOOD CENTERS INSTRUCTIONS: Send the form to ALL blood centers that provided blood components to this patient. Timely reporting is important, so that, if appropriate, the blood center may prevent the transfusion of other products from the same donor(s).

  Form, Report, Blood, Reporting, Reactions, Adverse, Transfusion, Report of transfusion adverse reaction, Report of transfusion adverse reaction to blood

GUIDELINES FOR MONITORING AND REPORTING …

THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH GUIDELINES FOR MONITORING AND REPORTING ADVERSE DRUG REACTIONS (ADRs) (Made under section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003)

  Guidelines, Reporting, Monitoring, Guidelines for monitoring and reporting

QRD Human Product Information Template

3 [For medicinal products subject to additional monitoring ONLY: The black symbol and the statements should only appear preceding section 1. The black symbol shall

  Information, Product, Human, Template, Qrd human product information template

Guideline for the notification of serious breaches of ...

311 January 2017 2 . EMA/430909/2016 3 . Guideline for the notification of serious breaches of . 4 . Regulation (EU) No 536/2014 or the clinical trial protocol

  Notification, Serious, Breaches, The notification of serious breaches of

COLOFAC 1. Product Name 2. Qualitative and …

Page 1 of 5 NEW ZEALAND DATA SHEET COLOFAC ® 1. Product Name Colofac, 135 mg, Tablet. 2. Qualitative and Quantitative Composition Each tablet contains 135 mg of Mebeverine hydrochloride.

  Compositions, Quantitative, Qualitative, Qualitative and quantitative composition

Medical Errors and Patient Safety - - RN.org®

found that over half of the adverse events at two major hospitals related to medical errors. It went on in chilling detail, describing people who had died from